Skip to main content

Table 2 Comparison of other genetic alterations between MDS patients with and without the DNMT3A mutation

From: Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

  

Number and percentage of patients with the mutation (%)

 

Mutation

No. examined

Total patients

DNMT3A-mutated patients

DNMT3A-wild patients

P value

IDH1

468

4 (0.9)

1 (2.7)

3 (0.7)

0.281

IDH2

464

19 (4.1)

7 (18.9)

12 (2.8)

< 0.001

ASXL1

459

108 (23.5)

5 (13.5)

103 (24.4)

0.160

EZH2

469

29 (6.2)

0 (0.0)

29 (6.7)

0.153

TET2

469

61 (13.0)

7 (18.9)

54 (12.5)

0.304

FLT3/ITD

465

5 (1.1)

0 (0)

5 (1.2)

> 0.999

JAK2

467

4 (0.9)

0 (0.0)

4 (0.9)

> 0.999

NRAS

469

25 (5.3)

2 (5.4)

23 (5.3)

> 0.999

KRAS

465

8 (1.7)

1 (2.7)

7 (1.6)

0.488

PTPN11

119

1 (0.8)

0 (0)

1 (1.0)

> 0.999

WT1

256

1 (0.4)

0 (0)

1 (0.4)

> 0.999

MLL/PTD

447

5 (1.1)

2 (5.4)

3 (0.7)

0.057

RUNX1

462

61 (13.2)

7 (18.9)

54 (12.7)

0.308

U2AF1

469

35 (7.5)

2 (5.4)

33 (7.6)

> 0.999

SRSF2

469

60 (12.8)

5 (13.5)

55 (12.7)

0.801

SF3B1

469#

48 (10.2)

11 (29.7)

37 (8.6)

< 0.001

 Lower-risk IPSS

249

33 (13.3)

7 (46.7)

26 (11.1)

0.001

 Higher-risk IPSS

188

11 (5.9)

3 (15)

8 (4.8)

0.098

SETBP1

466

15 (3.2)

0 (0)

15 (3.5)

0.621

TP53

465

42 (9.0)

4 (10.8)

38 (8.9)

0.763

  1. Abbreviations: No. number, ITD internal tandem duplication, PTD partial tandem duplication
  2. #Four hundred and thirty-seven of them had cytogenetic data and could be assigned to the IPSS-R risk groups